Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02718066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT02718066
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Enrollment
- 96 participants
Conditions and interventions
Interventions
- HBI-8000 in combination with nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2016
- Primary completion
- Aug 31, 2023
- Completion
- Aug 31, 2023
- Last update posted
- Nov 8, 2023
2016 – 2023
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| [Site 02] Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| [Site 11] University of California, San Diego Medical Center | La Jolla | California | 92037 | — |
| [Site 01] Hematology - Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. | Tampa | Florida | 33612 | — |
| [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute | Frederick | Maryland | 21702 | — |
| [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02718066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2023 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02718066 live on ClinicalTrials.gov.